Regulatory Insights

  1. What Sponsors Need To Know Before They Get To The IRB & IBC 5/13/2026

    Gene therapy requires early, rigorous safety planning and command of pediatric and biosafety rules. Early committee engagement reduces delays and strengthens high‑stakes trials.

  2. The State Of Materiovigilance: Capability Gaps, Technology Momentum, And Outsourcing Readiness 5/12/2026

    Explore how pharma and biotech companies are using AI, outsourcing, and new technologies to strengthen materiovigilance for complex drug-device products.

  3. Pharmacy Considerations For Early Phase Trials 5/8/2026

    This presentation explores practical pharmacy considerations in early-phase clinical trials, offering real-world insights from experienced clinical research pharmacists.

  4. Definitive QT Evaluation - Clinical And Operational Considerations 5/8/2026

    QT strategy decisions affect timelines, cost, and regulatory outcomes. This presentation examines when early QT data can support a waiver, how guidance updates influence study design, and more.

  5. How Remote Monitoring Is Transforming Compliance 5/8/2026

    Discover how remote monitoring is transforming pharmacy compliance. Shift from manual, onsite burdens to digital workflows that ensure real-time accuracy and continuous audit readiness.

  6. What The Joint FDA And EMA's AI Principles Can Mean For Clinical Trial Technology 5/6/2026

    New FDA/EMA principles align global expectations for AI in drug trials, emphasizing transparency, human-centric design, and risk-based governance to ensure data integrity and patient safety.

  7. A Blueprint For Modern Obesity Research 5/6/2026

    The landscape of obesity and GLP-1 research has reached a saturation point. To successfully scale to the 5,000-patient registries now required for long-term evidence, a shift in operational architecture is essential.

  8. Real-Time Data... Are We Fixing The Right Bottleneck (Or Any For That Matter)? 5/6/2026

    Real-time data streaming to regulators is a bold step, but true clinical acceleration requires solving site-level bottlenecks and data silos to reduce the administrative burden on research.

  9. Navigating The Waters Of Compliance In Clinical Research 5/5/2026

    Strengthen your research processes by adopting secure systems, staying current with regulatory standards, and ensuring your team is consistently trained to manage data responsibly and efficiently.

  10. How To Establish Strategic Readiness For First-In-Human Trials 4/29/2026

    Most teams realize too late that sequential planning creates delays. FIH readiness depends on aligning IND and clinical strategy early; otherwise, programs risk setbacks that stall execution and timelines.